GS-1720 is an experimental medication being tested for its effectiveness in treating people with HIV-1. It is taken orally once a week and is being studied to see if it can maintain viral suppression in patients who are already virologically suppressed.

GS-4182 is another experimental medication used in combination with GS-1720. It is also taken orally once a week. The combination of GS-1720 and GS-4182 is being evaluated to determine if it can effectively maintain viral suppression in people with HIV-1.

Biktarvy is a medication that combines three active ingredients: bictegravir, emtricitabine, and tenofovir alafenamide. It is used to treat HIV-1 and is taken daily. In this study, Biktarvy is used as a comparison to evaluate the effectiveness of the new weekly regimen of GS-1720 and GS-4182.

HIV-1 Infection – HIV-1 infection is caused by the human immunodeficiency virus type 1, which attacks the body’s immune system, specifically the CD4 cells (T cells). Over time, HIV-1 can destroy so many of these cells that the body can’t fight off infections and disease. The virus is transmitted through contact with certain body fluids of an infected person, most commonly during unprotected sex or through sharing needles. Initially, individuals may experience flu-like symptoms, but as the infection progresses, it can lead to more severe immune system damage. Without intervention, HIV-1 can advance to acquired immunodeficiency syndrome (AIDS), where the immune system is severely compromised. The progression of the disease can vary greatly among individuals, influenced by factors such as viral load and the individual’s overall health.